PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease

Affiliations

¹ 1] Department of Surgical Sciences (Dunedin), VU University Medical Center, Amsterdam, The Netherlands [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.
² Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands.
³ 1] QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Brisbane, Queensland, Australia [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.
⁴ 1] Centre for Inflammatory Bowel Disease, Fremantle Hospital, Fremantle, Western Australia, Australia [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.
⁵ 1] Flinders Medical Centre, Flinders University of South Australia, Bedford Park, South Australia, Australia [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.
⁶ 1] Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.
⁷ 1] Department of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.

Comment

Rebecca L Roberts et al. Am J Gastroenterol. 2014 Jun.

. 2014 Jun;109(6):925-7.

doi: 10.1038/ajg.2014.89.

¹ 1] Department of Surgical Sciences (Dunedin), VU University Medical Center, Amsterdam, The Netherlands [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.
² Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands.
³ 1] QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Brisbane, Queensland, Australia [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.
⁴ 1] Centre for Inflammatory Bowel Disease, Fremantle Hospital, Fremantle, Western Australia, Australia [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.
⁵ 1] Flinders Medical Centre, Flinders University of South Australia, Bedford Park, South Australia, Australia [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.
⁶ 1] Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.
⁷ 1] Department of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand [2] On behalf of the Australian and New Zealand Inflammatory Bowel Disease Consortium.

Erratum in

Am J Gastroenterol. 2015 Jan;110(1):204. Studd, Corrie [added]; Bell, Sally J [added]

No abstract available

PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.
Stocco G, Yang W, Crews KR, Thierfelder WE, Decorti G, Londero M, Franca R, Rabusin M, Valsecchi MG, Pei D, Cheng C, Paugh SW, Ramsey LB, Diouf B, McCorkle JR, Jones TS, Pui CH, Relling MV, Evans WE. Stocco G, et al. Hum Mol Genet. 2012 Nov 1;21(21):4793-804. doi: 10.1093/hmg/dds302. Epub 2012 Jul 30. Hum Mol Genet. 2012. PMID: 22846425 Free PMC article.